Prof. Mondher Toumi is M.D. by training, M.Sc. in Biological Sciences and Ph.D. in Economic Sciences. He is President and Founder of Creativ-Ceutical. Founder and Director of the European Market Access University Diploma, pioneer educational programme in market access held at the University of Aix-Marseille.

Prof. Mondher is member of the research unit 3279 in Public Health at Aix-Marseille University.

He worked from 1995 in the pharmaceutical industry for 13 years. Prof. Mondher was appointed Global Vice President at Lundbeck A/S in charge of health economics, outcome research, pricing, market access, epidemiology, risk management, governmental affairs and competitive intelligence. In 2008, he founded Creativ-Ceutical, an international consulting firm dedicated to support life science industries and authorities in strategic decision-making.

Prof. Mondher Toumi is also visiting Professor at two famous Chinese universities: Shenyang Pharmaceutical University and Beijing University (Third Hospital). In addition to contributing as a reviewer on several journals, he is Chief Editor at the online Journal of Market Access and Health Policy. He did two mandates as Co-Chair of the Research Review Committee ISPOR in 2012 and 2013.

Dr. Pierre Meulien is Executive Director of the Innovative Medicines Initiative (IMI).

From 2010 to 2015, Dr. Meulien was President and CEO of Genome Canada, where he raised significant funds for the organisation and oversaw the launch of novel projects and networks in the field of genomics-based technologies. Prior to that from 2007 to 2010, he was Chief Scientific Officer for Genome British Columbia.

From 2002 to 2007, Dr. Meulien served as founding CEO of the Dublin Molecular Medicine Centre (now Molecular Medicine Ireland), which linked medical schools and teaching hospitals in Dublin to build a critical mass in molecular medicine and translational research.

Dr. Meulien also worked in the private sector with the French biotechnology company Transgene, and with Aventis Pasteur (now Sanofi Pasteur). He has a PhD in molecular biology from the University of Edinburgh and carried out a post-doctoral fellowship at the Institut Pasteur in Paris.

Mr. Magill is Director of Business Development, Personalised Medicine & Connected Health at SAP, UK.

He has demonstrated history of working in the health tech and computer software industries. From 2009 to 2016 he was Head of Business Development at NorthWest EHealth, UK. He worked also as Informatics Project Manager at NHS.

Mr. Magill holds BA in Business, Management, Innovation, Data and Information Management.

Prof. Thirstrup is a medical doctor and board certified specialist in clinical pharmacology and therapeutics. He holds a PhD in pharmacology and has a long background in clinical internal medicine. Since 2012, he is an adjunct professor in pharmacotherapy at the Faculty of Health and Medical Sciences, University of Copenhagen.

From 2004-2009 prof. Thirstrup worked at the Danish Medicines Agency (DKMA) first as the Danish member of CHMP at the European Medicines Agency (EMA) for five years including 10 months as joint CHMP- and CAT-member, followed by a short period as head of Danish Institute for Rational Pharmacotherapy dealing with HTA and best practice guidelines for primary care.
In March 2013 he joined the pharmaceutical consultancy company NDA Group as a full-time medical advisor on NDA’s regulatory advisory board. In April 2014 prof. Thirstrup was appointed as Director for the Regulatory Advisory Board at NDA Regulatory Services Ltd.

Prof. Thirstrup is author of more than 30 scientific papers, guidelines and text-book chapters.

Prof. Sezerman graduated from Bogaziçi University, Istanbul, (B. Sc. Electrical. Eng. Dept., M.Sc. Biomedical Eng. Dept) and received his PhD in Biomedical Engineering from Boston University, MA, USA.

Currently, prof. Sezerman is Head of Biostatistics and Medical Informatics Department in Acıbadem Mehmet Ali Aydınlar Üniversitesi, Istanbul, Turkey. Previously he has worked at Boston University and Bogazici University as a researcher and an instructor. From 1999 to 2015 he worked at Sabanci University, Biological Sciences and Bioengineering Program, where he established the Computational Biology and Protein Engineering Laboratory.

His current research interests are in the field of Personalized and Precision Medicine, Protein Engineering, Drug and Vaccine Design, Functional Genomics, Metagenomics, Systems Biology and Bioinformatics.

Peter Kapitein is President and Patient Advocate of Inspire2Live.

Inspire2Live has been created to empower people to convert the sense of powerlessness, caused by cancer, into one of strength. Inspire2Live is founded on the absolute belief that one can attain the greatest possible satisfaction by putting their heart and soul into helping others. Its motto is “Never, ever quit!”.

Peter connects patients, researchers and clinicians to further research, treatments and care; in the Netherlands as well as internationally. He organizes congresses, lobbies the matrix of public authorities, health care organizations, insurance companies and health research institutes. Peter also gives lectures and talks to help patients and society to fight cancer where possible and live with cancer with a good quality of life. He is a writer of blogs, articles and books that also contributes to these topics.

Peter has been the co-founder of Alpe d’HuZes, the foundation that is most famous for the annual cycling event on Mount Alpe d’Huez. They raised over 100 million euro for the fight against cancer. Peter works at the Central Bank of the Netherlands as a program manager and advisor for complex and politically difficult problems. His employer facilitates him in his patient advocacy. Peter was honoured with a doctorate in October 2012 at the Free University in Amsterdam for connecting patients, researchers and clinicians all over the world and make them contribute to the quality of life of patients and their loved ones.

Bogi Eliasen is an associated partner at the Copenhagen Institute for Futures Studies (CIFS). He comes from the Faroe Islands and is educated in Political Science from the University of Aarhus, Denmark. He has been employed in the Faroe Business Affairs and Ministry of Foreign Affairs and worked as a consultant over the last ten years for politicians, the public sector and private companies.

Bogi is one of the initiators of the ambitious genome project FarGen which aims to sequence the genomes of the whole population of the Faroe Islands. As CIFS health expert Bogi sets the future stage of genomics and health framed with the holistic vision of making genomics usable.

He calls himself a knowledge broker whose expertise lies in combining various fields of knowledge.

Dr. Alexander Lezhava is leading the Translational Research Group at Genome Institute of Singapore. He is also a program director of POLARIS (Personalised OMIC Lattice for Advanced Research and Improving Stratification). The Translational Research Group mainly focus on molecular diagnostics to promote newly discovered bio-markers into tools for personalized patient care and is in line with POLARIS’ vision to translate local bio-marker discoveries into clinically-validated and implementable assays.

Before joining GIS, he worked in Singapore based company Dx assays as Research Director.

Alexander graduated from Tbilisi State University and obtained his PhD in Japan at Hiroshima University. After obtaining of Doctors degree, Alexander Lezhava joined the Ohio State University as a post- doctoral fellow. Later he moved to Japan where he worked more than 10 years as a unit leader at Omics Science Center, RIKEN Yokohama Institute.

Magda Chlebus is Executive Director Science Policy & Regulatory Affairs at the European Federation of Pharmaceutical Industries and Associations (EFPIA), representing the R&D-based pharmaceutical industry in Europe.

Ms. Chlebus and her team are in charge of following policy and legislative developments that influence the research and regulatory environments for the healthcare industry in Europe. This includes public private collaborations (inter alia the Innovative Medicines Initiative), enabling sensitive technologies and the interface between new science and technology and regulation.

After a Master Degree in Applied Linguistics at University of Warsaw in 1992 and a carrier as translator and teacher, in 1995 she joined EFPIA, the representative voice of R&D-based pharmaceutical industry in Europe.

Her experience covers public and government affairs, including designing and implementing advocacy campaigns on EU legislation as well as implementation of the pharmaceutical legislation in new Member States.

Prof. Dr. Ron van Schaik studied Chemistry at Utrecht University: specialisations Biochemistry, Molecular Biology and Clinical Chemistry. He did his PhD on Molecular cloning and Immunological localization of PLA2 at the Dept. Biochemistry of the Center of Biomembranes and Lipid Research (CBML) at Utrecht University, receiving his PhD.

A 4 year post-doc at the Dept. Endocrinology, Erasmus MC Rotterdam on Activin/Inhibin as biomarkers for solid tumors (1992-1996), was followed by a 1 year post-doc at the Daniel den Hoed Cancer Center on K-ras detection in stool as a marker for early detection of colon cancer. In 1998, he joined the Dept. Clinical Chemistry at Erasmus MC on a project on Pharmacogenetics, where he was resident Clinical Chemistry at that department, receiving his Dutch and European registration (EuSpML) in April 2003. Prof. van Schaik continued to work at the Dept. Clinical Chemistry, becoming an Associate Professor in 2008 and a Full Professor Pharmacogenetics in 2013.

He is now Director of the Dutch Expertcenter and International (IFCC) Reference Center for Pharmacogenetics, Dept. Clinical Chemistry Erasmus MC Rotterdam, leading the Unit Research & Development and is responsible for laboratory testing in Emergency Medicine and Cardiology.

His work focusses on clinical implementation of Pharmacogenetics, with research on Immunosuppression, Oncology, Pain, and Psychiatry. Additional research areas: Prostate Cancer Biomarkers and Cardiac Markers. In 2001, he received the Ortho Clinical Diagnostics Award for Outstanding Research, in 2009 the AACC Outstanding Speaker Award, and in 2010 the AACC/Mol Pathology Award for Outstanding Scientific Research.

Prof. van Schaik participates in National and International committees on Pharmacogenetics (IFCC, AACC, ESPT, EFLM, IATDMCT, NVKC, KNMP, EMA).

Dr. Dalsgaard is Senior Vice President, Head of Experimental Medicine & Clinical Development at Lundbeck, Denmark. He is a medical doctor, Surgery/Internal Medicine and Neurology.

He graduated as Medical Doctor at the University of Copenhagen and holds a Doctor of Medicinal Science Degree (DMSc., dr. med) with a Thesis on human brain metabolism. Dr. Dalsgaard also has an Executive MBA Degree from IMD Business School.

Dr. Rossen Koytchev is a medical doctor and specialist in Clinical Pharmacology. He is one of the founding members of CCDRD AG, a pioneer in clinical biosimilar development located in Hoppegarten, Germany, and took over the position of CEO in 2001.

Dr. Koytchev has overseen the planning, management, evaluation and medical writing of more than 900 phase I-IV clinical trials. On behalf of CCDRD AG clients, he is directly involved in numerous scientific advice procedures with European regulators.